Brief: NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England
Aug 22 (Reuters) -
NHS:
* NHS-AWAITS FINAL DECISION FROM NICE FOR CLINICAL BENEFITS,
COST-EFFECTIVENESS OF LECANEMAB TO DETERMINE IF IT SHOULD BE
OFFERED BY NHS IN ENGLAND
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million